Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

Copper-Heparin Inhalation Therapy To Repair Emphysema: A Scientific Rationale.

Janssen R, Wouters EF, Janssens W, Daamen WF, Hagedoorn P, de Wit HA, Serré J, Gayan-Ramirez G, Franssen FM, Reynaert NL, von der Thüsen JH, Frijlink HW.

Int J Chron Obstruct Pulmon Dis. 2019 Nov 25;14:2587-2602. doi: 10.2147/COPD.S228411. eCollection 2019.

2.

Dispersibility and Storage Stability Optimization of High Dose Isoniazid Dry Powder Inhalation Formulations with L-Leucine or Trileucine.

Sibum I, Hagedoorn P, Kluitman MPG, Kloezen M, Frijlink HW, Grasmeijer F.

Pharmaceutics. 2019 Dec 25;12(1). pii: E24. doi: 10.3390/pharmaceutics12010024.

3.

Pulmonary immunization: deposition site is of minor relevance for influenza vaccination but deep lung deposition is crucial for hepatitis B vaccination.

Tomar J, Tonnis WF, Patil HP, de Boer AH, Hagedoorn P, Vanbever R, Frijlink HW, Hinrichs WLJ.

Acta Pharm Sin B. 2019 Nov;9(6):1231-1240. doi: 10.1016/j.apsb.2019.05.003. Epub 2019 May 28.

4.

A comparative analysis of changes in pMDI drug dose delivery before and after detergent coating using five antistatic valved holding chambers.

Hagedoorn P, Bawary W, Frijlink HW, Grasmeijer F.

J Allergy Clin Immunol Pract. 2019 Oct 5. pii: S2213-2198(19)30847-5. doi: 10.1016/j.jaip.2019.09.021. [Epub ahead of print] No abstract available.

5.

Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson's disease.

Luinstra M, Rutgers W, van Laar T, Grasmeijer F, Begeman A, Isufi V, Steenhuis L, Hagedoorn P, de Boer A, Frijlink HW.

Ther Adv Chronic Dis. 2019 Jun 21;10:2040622319857617. doi: 10.1177/2040622319857617. eCollection 2019.

6.

Nasal gene expression changes with inhaled corticosteroid treatment in asthma.

Boudewijn IM, Lan A, Faiz A, Cox CA, Brouwer S, Schokker S, Vroegop SJ, Nawijn MC, Woodruff PG, Christenson SA, Hagedoorn P, Frijlink HW, Choy DF, Brouwer U, Wisman M, Postma DS, Fingleton J, Beasley R, van den Berge M, Guryev V.

Allergy. 2020 Jan;75(1):191-194. doi: 10.1111/all.13952. Epub 2019 Jul 15. No abstract available.

PMID:
31230369
7.

Characterization and Formulation of Isoniazid for High-Dose Dry Powder Inhalation.

Sibum I, Hagedoorn P, Frijlink HW, Grasmeijer F.

Pharmaceutics. 2019 May 13;11(5). pii: E233. doi: 10.3390/pharmaceutics11050233.

8.

Severe asthma: Entering an era of new concepts and emerging therapies: Highlights of the 4th international severe asthma forum, Madrid, 2018.

Seys SF, Quirce S, Agache I, Akdis CA, Alvaro-Lozano M, Antolín-Amérigo D, Bjermer L, Bobolea I, Bonini M, Bossios A, Brinkman P, Bush A, Calderon M, Canonica W, Chanez P, Couto M, Davila I, Del Giacco S, Del Pozo V, Erjefält JS, Gevaert P, Hagedoorn P, G Heaney L, Heffler E, Hellings PW, Jutel M, Kalayci O, Kurowski MM, Loukides S, Nair P, Palomares O, Polverino E, Sanchez-Garcia S, Sastre J, Schwarze J, Spanevello A, Ulrik CS, Usmani O, Van den Berge M, Vasakova M, Vijverberg S, Diamant Z.

Allergy. 2019 Nov;74(11):2244-2248. doi: 10.1111/all.13843. Epub 2019 May 31. No abstract available.

PMID:
31021446
9.

Associations of AMP and adenosine induced dyspnea sensation to large and small airways dysfunction in asthma.

Cox CA, Boudewijn IM, Vroegop SJ, Schokker S, Lexmond AJ, Frijlink HW, Hagedoorn P, Vonk JM, Farenhorst MP, Ten Hacken NHT, Kerstjens HAM, van den Berge M.

BMC Pulm Med. 2019 Jan 28;19(1):23. doi: 10.1186/s12890-019-0783-0.

10.

Predictors of clinical response to extrafine and non-extrafine particle inhaled corticosteroids in smokers and ex-smokers with asthma.

Gafar F, Boudewijn IM, Cox CA, Vonk JM, Schokker S, Lexmond AJ, Frijlink HW, Hagedoorn P, Postma DS, van den Berge M.

Respir Res. 2018 Dec 18;19(1):256. doi: 10.1186/s12931-018-0961-2.

11.

Challenges for pulmonary delivery of high powder doses.

Sibum I, Hagedoorn P, de Boer AH, Frijlink HW, Grasmeijer F.

Int J Pharm. 2018 Sep 5;548(1):325-336. doi: 10.1016/j.ijpharm.2018.07.008. Epub 2018 Jul 2. Review.

12.

Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis.

Akkerman OW, Grasmeijer F, de Lange WCM, Kerstjens HAM, de Vries G, Bolhuis MS, Alffenaar JW, Frijlink HW, Smith G, Gajraj R, de Zwaan R, Hagedoorn P, Dedicoat M, van Soolingen D, van der Werf TS.

Eur Respir J. 2018 Mar 22;51(3). pii: 1702490. doi: 10.1183/13993003.02490-2017. Print 2018 Mar. No abstract available.

13.

Extrafine compared to non-extrafine particle inhaled corticosteroids in smokers and ex-smokers with asthma.

Cox CA, Boudewijn IM, Vroegop SJ, Schokker S, Lexmond AJ, Frijlink HW, Hagedoorn P, Vonk JM, Farenhorst MP, Ten Hacken NHT, Kerstjens HAM, Postma DS, van den Berge M.

Respir Med. 2017 Sep;130:35-42. doi: 10.1016/j.rmed.2017.07.005. Epub 2017 Jul 8.

14.

Targeting the small airways with dry powder adenosine: a challenging concept.

van der Wiel E, Lexmond AJ, van den Berge M, Postma DS, Hagedoorn P, Frijlink HW, Farenhorst MP, de Boer AH, Ten Hacken NHT.

Eur Clin Respir J. 2017 Sep 6;4(1):1369328. doi: 10.1080/20018525.2017.1369328. eCollection 2017.

15.

Prerequisites for a dry powder inhaler for children with cystic fibrosis.

Lexmond AJ, Hagedoorn P, Frijlink HW, Rottier BL, de Boer AH.

PLoS One. 2017 Aug 11;12(8):e0183130. doi: 10.1371/journal.pone.0183130. eCollection 2017.

16.

Bronchial Provocation Testing Can Be Improved by Using Dry Powder Adenosine Instead of Nebulized Adenosine Monophosphate.

Lexmond AJ, Boudewijn IM, Hagedoorn P, Schokker S, Cox CA, Vonk JM, Ten Hacken NHT, Frijlink HW, Vroegop SJ, van den Berge M.

Am J Respir Crit Care Med. 2018 Feb 1;197(3):391-394. doi: 10.1164/rccm.201704-0715LE. No abstract available.

PMID:
28650210
17.

Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients.

Hoppentocht M, Akkerman OW, Hagedoorn P, Alffenaar JW, van der Werf TS, Kerstjens HA, Frijlink HW, de Boer AH.

PLoS One. 2016 Mar 9;11(3):e0149768. doi: 10.1371/journal.pone.0149768. eCollection 2016.

18.

A levodopa dry powder inhaler for the treatment of Parkinson's disease patients in off periods.

Luinstra M, Grasmeijer F, Hagedoorn P, Moes JR, Frijlink HW, de Boer AH.

Eur J Pharm Biopharm. 2015 Nov;97(Pt A):22-9. doi: 10.1016/j.ejpb.2015.10.003. Epub 2015 Oct 13.

19.

Recent advances in the fundamental understanding of adhesive mixtures for inhalation.

Grasmeijer F, Grasmeijer N, Hagedoorn P, Frijlink HW, Haaije de Boer A.

Curr Pharm Des. 2015;21(40):5900-14. Review.

PMID:
26446471
20.

Can 'extrafine' dry powder aerosols improve lung deposition?

de Boer AH, Gjaltema D, Hagedoorn P, Frijlink HW.

Eur J Pharm Biopharm. 2015 Oct;96:143-51. doi: 10.1016/j.ejpb.2015.07.016. Epub 2015 Jul 26.

Supplemental Content

Loading ...
Support Center